Aspira Women’s Health to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10
Aspira Women’s Health Inc. (Nasdaq: AWH) announced it will release its third-quarter financial results for the period ending September 30, 2022, on November 10, 2022. The company will hold a conference call at 8:30 AM ET that day to discuss the results and provide a corporate update. Aspira focuses on women's health through innovative testing options and bio-analytical solutions, aiming to improve gynecologic health outcomes. This includes addressing disparities in ovarian cancer risk assessment and developing solutions for pelvic diseases.
- Focus on innovative solutions in women's health.
- Addressing ethnic disparity in ovarian cancer risk assessment.
- None.
AUSTIN, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that the company will report its financial results for the third quarter ended September 30, 2022 before the market open on Thursday, November 10, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30 am Eastern Time. Details for the call are below:
| Conference Call & Webcast: | |
| Date: | Thursday, November 10 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-877-407-4018 |
| International: | 1-201-689-8471 |
| Conference ID: | 13730748 |
| Webcast | Click HERE |
The webcast will also be available on the Events & Presentation page of the Aspira Women’s Health Investor Relations website. An archive of the webcast replay will be available on the Company’s website for up to 90 days.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc.SM is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus® combines our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX™ testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is working to deliver a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development include OvaWatch™ and EndoCheck™. To improve patient accessibility, Aspira Women’s Health has launched our Aspira SynergySM technology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house. Visit our website for more information at www.aspirawh.com.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: 617-430-7577
Arr@lifesciadvisors.com
FAQ
When will Aspira Women’s Health report its third-quarter earnings?
What time is the conference call for Aspira Women’s Health?
What is the purpose of the conference call on November 10, 2022?
What is the stock symbol for Aspira Women’s Health?
